DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Micardis HCT (Telmisartan / Hydrochlorothiazide) - Summary

 
 



USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, MICARDIS HCT tablets should be discontinued as soon as possible (see WARNINGS, Fetal/Neonatal Morbidity and Mortality).

 

MICARDIS HCT SUMMARY

MICARDIS® HCT (telmisartan/hydrochlorothiazide) is a combination of telmisartan, an orally active angiotensin II antagonist acting on the AT1 receptor subtype, and hydrochlorothiazide, a diuretic.

MICARDIS® HCT (telmisartan/hydrochlorothiazide) is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION).
See all Micardis HCT indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Micardis HCT (Telmisartan / Hydrochlorothiazide)

Calorie restriction improves sleep apnea, hypertension in obese people
Source: Hypertension News From Medical News Today [2014.09.12]
Restricting calories may improve obstructive sleep apnea and reduce high blood pressure in obese adults, according to a study presented at the American Heart Association's High Blood Pressure...

Hypertension up to Six Times More Likely in Obese vs Slim Youth
Source: theheart.org | Medscape Cardiology Headlines [2014.09.10]
Overweight and obese boys and girls were much more likely to have hypertension than normal-weight children in a new study; thus, weight loss should be encouraged to reduce later CVD risk.
Heartwire

Hypertension is a nearly 6 fold risk factor in obese youths
Source: Hypertension News From Medical News Today [2014.09.03]
Obese youths have a nearly six fold risk of hypertension, according to research in more than 22 000 young people from the PEP Family Heart Study presented at ESC Congress by Professor Peter Schwandt...

Stroke risk increased by resistant hypertension: 35 percent in women and 20 percent in elderly Taiwanese
Source: Hypertension News From Medical News Today [2014.09.03]
Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research presented at ESC Congress by Dr Kuo-Yang Wang from Taiwan.

Potential to treat pulmonary hypertension with protein in 'good cholesterol'
Source: Cholesterol News From Medical News Today [2014.09.01]
Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis.

more news >>

Published Studies Related to Micardis HCT (Telmisartan / Hydrochlorothiazide)

Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild to moderate hypertension. [2009.01]
Among angiotensin receptor blockers (ARBs), telmisartan is suggested to function as a partial agonist of peroxisome proliferator-activated receptor-gamma (PPAR gamma) and to improve lipid and glucose metabolism. Clinical benefits of telmisartan over other ARBs may be apparent in combination with diuretics, which have harmful influences on lipid and glucose metabolism...

The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. [2008.06]
BACKGROUND: To compare the tolerability and safety of telmisartan +/- hydrochlorothiazide (HCTZ)... CONCLUSION: The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities.

Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. [2008.02]
In 2004-2005, the antihypertensive effects of telmisartan 80 mg versus valsartan 160 mg combined with hydrochlorothiazide 25 mg were assessed in a large placebo-controlled trial in patients with stages 1 and 2 hypertension and demonstrated that both agents were highly effective in lowering blood pressure (BP) compared with placebo and that telmisartan lowered BP significantly greater than valsartan...

Nilotinib. [2008]
Nilotinib is an orally administered BCR-ABL tyrosine kinase inhibitor that has shown good clinical efficacy in imatinib-resistant or -intolerant, Philadelphia chromosome-positive, chronic myeloid leukaemia (CML) in a phase I/II trial. The phase I component of the trial established the dosage regimen used in the phase II part of the trial, which included several arms...

Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. [2006.03]
The aim of this study was to compare the effects of telmisartan/hydrochlorothiazide (HCTZ) vs lisinopril/HCTZ combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. A total of 160 patients, 76 men and 84 women, aged 61-75 years, with sitting diastolic blood pressure (DBP)>90 mmHg and <110 mmHg and systolic blood pressure (SBP)>140 mmHg were randomized to receive temisartan 80 mg/HCTZ 12.5 mg o.d...

more studies >>

Clinical Trials Related to Micardis HCT (Telmisartan / Hydrochlorothiazide)

Telmisartan80mg/hydrochlothiazide12.5mg (Micardis Plus) ABPM Study in China [Completed]
to evaluate the trough and peak effect of once daily MICARDIS PLUS? (Telmisartan 80mg / hydrochlorot hiazide 12. 5 mg) by 24 ABPM in patients with mild to moderate essential hypertension

INNOVATION Study - Telmisartan (Micardis?) in Incipient Diabetic Nephropathy [Completed]
The aim of this study is to compare the preventive effect of Telmisartan (Micardis?) versus placebo control on the transition to overt nephropathy in patients with diabetic nephropathy manifesting mic roalbuminuria associated with type II diabetes, and to evaluate the efficacy and safety of Telmisart an (Micardis?, Gliosartan?, Kinzal?, Kinzalmono?, Predxal?, Pritor?, Samertan?, Telmisartan?) for di abetic nephropathy patients.

PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg [Recruiting]
PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular events. The study aims to evaluate the safety, efficacy and protection of Micardis 80mg/Micardis plus 80/12. 5mg from cardiovascular risks in patients with essential hypertension

CKD-828 Telmisartan Non-Responder Trial [Recruiting]
The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2. 5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately controlled by telmisartan monotherapy.

Telmisartan80/HCTZ25 Versus telmisartan80/HCTZ12.5 in Hypertension Not Responding to telmisartan80/HCTZ12.5 [Completed]
The primary objective of this trial is to demonstrate that a fixed dose combination of telmisartan 8 0 mg plus hydrochlorothiazide 25 mg (T80/H25) is superior in reducing blood pressure after eight wee ks compared with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12. 5 mg (T80

/H12. 5) in patients who fail to respond to six weeks treatment with T80/H12. 5.

more trials >>

Reports of Suspected Micardis HCT (Telmisartan / Hydrochlorothiazide) Side Effects

Blood Pressure Increased (9)Dyspnoea (9)Hyponatraemia (9)Haematoma (8)Pollakiuria (8)Renal Failure Acute (7)Hypertension (7)Drug Ineffective (6)Injection Site Haemorrhage (6)Rales (6)more >>


Page last updated: 2014-09-12

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014